Scintigraphic load of bone disease evaluated by DASciS software as a survival predictor in metastatic castration-resistant prostate cancer patients candidates to 223RaCl treatment
, , , , , , , und
19. Dez. 2019
Über diesen Artikel
Artikel-Kategorie: Research Article
Online veröffentlicht: 19. Dez. 2019
Seitenbereich: 40 - 47
Eingereicht: 18. Juni 2019
Akzeptiert: 22. Okt. 2019
DOI: https://doi.org/10.2478/raon-2019-0058
Schlüsselwörter
© 2020 Viviana Frantellizzi, Arianna Pani, Maria Dea Ippoliti, Alessio Farcomeni, Irvin Aloise, Mirco Colosi, Claudia Polito, Roberto Pani, Giuseppe De Vincentis, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Univariate and multivariable analysis of overall survival (OS) in relation to baseline variables
| Clinical covariates | Univariate HR (95% models CI) | p-value | Multivariable HR (95% CI) model | p-value |
|---|---|---|---|---|
| 1.80 (1.61–2.02) | < 0.001 | 1.79 (1.59–2.01) | < 0.001 | |
| 1.02 (0.99–1.05) | 0.184 | |||
| 0.94 (0.89–1.00) | 0.057 | |||
| 0.97 (0.91–1.04) | 0.414 | |||
| 1.97 (1.48–2.64) | < 0.001 | 1.74 (1.29–2.36) | < 0.001 | |
| 1.35 (1.12–1.164) | 0.002 | |||
| 0.73 (0.64–0.84) | < 0.001 | |||
| 1.51 (1.19–1.92) | < 0.001 | |||
| 1.06 (1.02–1.12) | 0.006 | |||
| 1.11 (1.06–1.17) | < 0.001 |
Expected survival for baseline bone scan index (BSI) intervals
| % BSI | Patients number (n = 127) | Median survival (months) | 0.95 LowCL (months) | 0.95 UpCL (months) |
|---|---|---|---|---|
| 59 | 28 | 19 | NA | |
| 33 | 11 | 9 | 12 | |
| 35 | 5 | 5 | 7 |
Baseline patients’ characteristics
| Baseline variable | Patients (n = 127) | % |
|---|---|---|
| Age (years) | ||
| Mean (range) | 73.82 (59–90) | |
| Heigth (m) | ||
| Mean (range) | 1.71 (1.58–1.95) | |
| Weight (kg) | ||
| Mean (range) | 78.60 (59–120) | |
| BMI | ||
| Mean (range) | 26.75 (19.57–39.18) | |
| Gleason score | ||
| Mean (range) | 6.3 (5–10) | |
| 5 | 1 | 0.79 |
| 6 | 3 | 2.36 |
| 7 | 38 | 29.92 |
| 8 | 30 | 23.62 |
| 9 | 28 | 22.04 |
| 10 | 2 | 1.59 |
| Unknown | 25 | 19.68 |
| ECOG Performance status | ||
| Mean (range) | 0.86 (0–3) | |
| 0 | 39 | 30.7 |
| 1 | 68 | 53.54 |
| 2–3 | 20 | 15.75 |
| Extent of skeletal disease | ||
| < 6 metastases | 18 | 14.17 |
| 6–20 metastases | 46 | 36.22 |
| > 20 metastases | 63 | 49.61 |
| No. of previous systemic treatments after | ||
| castration resistance (Docetaxel, Cabazitaxel, | ||
| Abiraterone, Enzalutamide) | ||
| 0 | 32 | 25.19 |
| 1 | 42 | 33.07 |
| 2 | 32 | 25.19 |
| ≥ 3 | 21 | 16.53 |
| No. of therapy’s cycles administered | ||
| Mean (range) | 5.56 (2–6) | |
| 2 | 3 | 2.36 |
| 3 | 3 | 2.36 |
| 4 | 10 | 7.87 |
| 5 | 14 | 11.02 |
| 6 | 97 | 76.38 |
| No. of systemic treatments after Radium223 | ||
| Docetaxel | 11 | 8.6 |
| Cabazitaxel | 0 | 0 |
| Abiraterone | 2 | 1.5 |
| Enzalutamide | 6 | 4.7 |
| Baseline Hb | ||
| Median (range) | 12.14 (7.5–15) | |
| < 12 g/dl | 54 | 42.51 |
| ≥ 12 g/dl | 73 | 57.48 |
| Baseline tALP* | ||
| Median (range) | 300 (34–1750) | |
| < 226 U/l | 79 | 62.2 |
| ≥ 226 U/l | 48 | 87.8 |
| Baseline PLT (103/mm | ||
| Median (range) | 249 (74–763) | |
| Baseline PSA | ||
| < 20 ng/ml | 42 | 33.07 |
| ≥ 20 ng/ml | 85 | 66.92 |